{"id":59637,"date":"2026-03-16T20:11:07","date_gmt":"2026-03-16T12:11:07","guid":{"rendered":"https:\/\/flcube.com\/?p=59637"},"modified":"2026-03-16T20:11:08","modified_gmt":"2026-03-16T12:11:08","slug":"cms-secures-nmpa-approval-for-desidustat-first-domestic-hif-phi-for-non-dialysis-ckd-anemia-enters-china-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59637","title":{"rendered":"CMS Secures NMPA Approval for Desidustat \u2013 First Domestic HIF-PHI for Non-Dialysis CKD Anemia Enters China Market"},"content":{"rendered":"\n

China Medical System Holdings (CMS; HKG: 0867<\/a>)<\/strong> announced marketing approval<\/strong> from China’s National Medical Products Administration (NMPA)<\/strong> for desidustat<\/strong>, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)<\/strong> for the treatment of anemia in adult chronic kidney disease (CKD) patients without dialysis<\/strong>. The approval, based on successful Phase III data<\/strong> demonstrating sustained hemoglobin control<\/strong> and favorable long-term safety<\/strong>, positions CMS to capture share in China’s expanding renal anemia market.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Approval Type<\/strong><\/td>Marketing authorization (Category 1 innovative drug)<\/td><\/tr>
Product<\/strong><\/td>Desidustat (oral HIF-PHI)<\/td><\/tr>
Developer<\/strong><\/td>China Medical System Holdings (CMS; HKG: 0867)<\/td><\/tr>
Indication<\/strong><\/td>Anemia in adult CKD patients not on dialysis<\/strong><\/td><\/tr>
Significance<\/strong><\/td>First domestically developed HIF-PHI<\/strong> approved in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence<\/h2>\n\n\n\n
Endpoint<\/th>Phase III Result<\/th>Clinical Impact<\/th><\/tr><\/thead>
Primary Efficacy<\/strong><\/td>Met primary endpoint<\/td>Non-inferior\/superior Hb elevation vs. standard of care<\/td><\/tr>
Long-Term Hb Maintenance<\/strong><\/td>Sustained target Hb levels during extension period<\/td>Reduced transfusion burden; improved quality of life<\/td><\/tr>
Hepcidin Reduction<\/strong><\/td>Significant decrease in hepcidin levels<\/td>Addresses functional iron deficiency\u2014key CKD anemia driver<\/td><\/tr>
Iron Metabolism<\/strong><\/td>Correction of iron metabolism disorders<\/td>Enhanced iron availability for erythropoiesis<\/td><\/tr>
Safety Profile<\/strong><\/td>Favorable long-term tolerability<\/td>Supports chronic outpatient administration<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Market Position<\/h2>\n\n\n\n
Attribute<\/th>Desidustat Specification<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>HIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitor)<\/td><\/tr>
Route<\/strong><\/td>Oral (convenient vs. injectable ESAs)<\/td><\/tr>
Target Population<\/strong><\/td>~50 million non-dialysis CKD patients<\/strong> in China; ~40% anemic<\/strong><\/td><\/tr>
Differentiation<\/strong><\/td>Oral dosing + iron metabolism correction vs. erythropoiesis-stimulating agents (ESAs) and IV iron<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Competitive Landscape:<\/strong><\/p>\n\n\n\n